Korean Drug

고려제약 · 014570

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$27.7M (₩38.2B)

Overview

Korean Drug makes over-the-counter medicines, including a well-known cold remedy called Haben, as well as prescription drugs targeting central nervous system conditions such as epilepsy, stroke, and Parkinson's disease.

Its products reach patients through pharmacies and hospitals across South Korea. Listed on KOSDAQ, the company's core revenue driver is its central nervous system drug line, which it describes as its lead product category, alongside a broader portfolio spanning digestive, dermatological, antibiotic, and vitamin products.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$45.3M
▼ −14.4% YoY
Operating profit · FY2025
US$5M
▼ −24.4% YoY
Net income · FY2025
US$4.7M
▲ +117.4% YoY

Revenue

  • FY2023US$59M
  • FY2024US$52.9M
  • FY2025US$45.3M

Operating profit

  • FY2023US$13.1M
  • FY2024US$6.6M
  • FY2025US$5M

Net income

  • FY2023−US$3.6M
  • FY2024US$2.2M
  • FY2025US$4.7M

Key ratios (FY2025)

ROE
7.8%
Debt/Eq
13.5%
Op. margin
11.1%
Net margin
10.4%
Rev. YoY
▼ −14.4%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.